Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05300724




Registration number
NCT05300724
Ethics application status
Date submitted
18/03/2022
Date registered
29/03/2022
Date last updated
10/06/2024

Titles & IDs
Public title
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Scientific title
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Secondary ID [1] 0 0
2022-000046-15
Secondary ID [2] 0 0
GE43220
Universal Trial Number (UTN)
Trial acronym
HONU
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Age-Related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - No intervention

Intermediate AMD - Participants with iAMD will be evaluated for the progression of iAMD to more advanced atrophic AMD stages, such as nascent geographic atrophy (nGA) or incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), and subsequently from nGA or iRORA to complete retinal pigment epithelium (cRORA) and outer retinal atrophy or geographic atrophy (GA), on Day 1 and thereafter every 12 weeks up to the end of the Observation Period, approximately 3 years.


Other interventions: No intervention
No intervention will be administered in this study.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Rate of Conversion from iAMD to nGA /iRORA
Timepoint [1] 0 0
Baseline up to 3 years
Primary outcome [2] 0 0
Rate of Conversion from nGA/iRORA to cRORA/GA
Timepoint [2] 0 0
Baseline up to 3 years
Primary outcome [3] 0 0
Rate of Photoreceptor Loss as Assessed by Spectral Domain Optical Coherence Tomography (SD-OCT)
Timepoint [3] 0 0
Baseline up to 3 years

Eligibility
Key inclusion criteria
- For women of childbearing potential, agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraception, during the study for at least 28 days
after the last fluorescein injection for the fluorescein angiography (FA)
administration

- Study eye: High-risk intermediate AMD
Minimum age
50 Years
Maximum age
94 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Macular disease in either eye with subretinal deposits not typical of AMD

- Pigmentary abnormalities of the retina in either eye not typical of AMD

- Atrophy in either eye due to causes other than AMD

- Study eye: Any concurrent or history of ocular or intraocular condition

- Study eye: Intraocular surgery, including cataract surgery, within 3 months prior to
Day 1

- Study eye: Retinal tears or peripheral retinal breaks within 3 months prior to Day 1

- Study eye: Concurrent or history of retinal laser photocoagulation or anti-vascular
endothelial growth factor (anti-VEGF) treatment for exudative MNV, diabetic macular
edema, retinal vein occlusion, or proliferative diabetic retinopathy

- Study eye: Presence of choroidal nevus with overlying drusen in the circle with a
radius 3600 micrometer centered on the fovea

- Study eye: Previous participation in interventional clinical trials for GA or early
stages of AMD, except for vitamins and minerals, regardless of the route of
administration within the last 6 months, except for sham-arm participants

- Study eye: History of glaucoma surgery, corneal transplant, retinal pigment epithelium
tear, retinal tear that involves the macula, retinal detachment

- Either eye: Uncontrolled progressive glaucoma

- Either eye: Moderate or severe non-proliferative diabetic retinopathy or proliferative
diabetic retinopathy

- Either eye: History of recurrent infectious or inflammatory ocular disease

- Any concurrent or history of taking medications that can induce retinal toxicity

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/05/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2026
Actual
Sample size
Target
400
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Marsden Eye Specialists - Parramatta
Recruitment hospital [2] 0 0
Sydney Eye Hospital - Sydney
Recruitment hospital [3] 0 0
Sydney Retina Clinic and Day Surgery - Sydney
Recruitment hospital [4] 0 0
Adelaide Eye and Retina Centre - Adelaide
Recruitment hospital [5] 0 0
Centre For Eye Research Australia - East Melbourne
Recruitment hospital [6] 0 0
The Lions Eye Institute - Nedlands
Recruitment postcode(s) [1] 0 0
2150 - Parramatta
Recruitment postcode(s) [2] 0 0
2000 - Sydney
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
West Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
France
State/province [29] 0 0
Creteil
Country [30] 0 0
France
State/province [30] 0 0
Ecully
Country [31] 0 0
France
State/province [31] 0 0
Grenoble
Country [32] 0 0
France
State/province [32] 0 0
Lyon
Country [33] 0 0
France
State/province [33] 0 0
Paris
Country [34] 0 0
France
State/province [34] 0 0
Strasbourg
Country [35] 0 0
Germany
State/province [35] 0 0
Bonn
Country [36] 0 0
Germany
State/province [36] 0 0
Freiburg
Country [37] 0 0
Germany
State/province [37] 0 0
Gottingen
Country [38] 0 0
Germany
State/province [38] 0 0
Hannover
Country [39] 0 0
Germany
State/province [39] 0 0
Leipzig
Country [40] 0 0
Germany
State/province [40] 0 0
Münster
Country [41] 0 0
Germany
State/province [41] 0 0
Tübingen
Country [42] 0 0
Israel
State/province [42] 0 0
Haifa
Country [43] 0 0
Israel
State/province [43] 0 0
Jerusalem
Country [44] 0 0
Israel
State/province [44] 0 0
Petach Tikva
Country [45] 0 0
Israel
State/province [45] 0 0
Tel Aviv-Yafo
Country [46] 0 0
Italy
State/province [46] 0 0
Friuli-Venezia Giulia
Country [47] 0 0
Italy
State/province [47] 0 0
Lazio
Country [48] 0 0
Italy
State/province [48] 0 0
Lombardia
Country [49] 0 0
Puerto Rico
State/province [49] 0 0
Arecibo

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Genentech, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter prospective study in participants with intermediate age-related macular
degeneration (iAMD). One primary objective of this study is to assess iAMD disease
progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more
advanced atrophic AMD stages. The other primary objective of this observational study is to
assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical
endpoint. The study will consist of an observation period of approximately 3 years (~144
weeks) for participants.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05300724
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
GE43220 https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. Only)
Fax 0 0
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05300724